Boston Common Asset Management, LLC Bio N Tech Se Transaction History

Boston Common Asset Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 11, 2024	SELL	$88.96 - $112.35 $587,047 - $741,397	-6,599 Reduced 20.39%	25,771 $2.38 Million
Q4 2023 Jan 09, 2024	SELL	$90.91 - $112.75 $11 Million - $13.6 Million	-120,620 Reduced 78.84%	32,370 $3.42 Million
Q3 2023 Oct 11, 2023	SELL	$98.5 - $125.08 $9.1 Million - $11.6 Million	-92,395 Reduced 37.65%	152,990 $16.6 Million
Q2 2023 Jul 24, 2023	SELL	$102.58 - $129.66 $1.98 Million - $2.5 Million	-19,257 Reduced 7.28%	245,385 $26.5 Million
Q1 2023 May 17, 2023	SELL	$122.57 - $153.67 $632,583 - $793,090	-5,161 Reduced 1.91%	264,642 $33 Million
Q4 2022 Jan 26, 2023	SELL	$118.43 - $186.05 $1.19 Million - $1.88 Million	-10,084 Reduced 3.6%	269,803 $40.5 Million
Q3 2022 Oct 20, 2022	SELL	$127.65 - $183.11 $496,430 - $712,114	-3,889 Reduced 1.37%	279,887 $37.8 Million
Q2 2022 Aug 10, 2022	BUY	$123.25 - $186.24 $443,083 - $669,532	3,595 Added 1.28%	283,776 $42.3 Million
Q1 2022 May 16, 2022	BUY	$126.25 - $231.85 $11 Million - $20.3 Million	87,511 Added 45.42%	280,181 $47.8 Million
Q4 2021 Jan 31, 2022	BUY	$216.64 - $362.52 $41.7 Million - $69.8 Million	192,670 New	192,670 $49.7 Million

360

38.3M

2.45M

2.29M

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $30B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

Get notified when there are updates to the investment portfolio of Boston Common Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boston Common Asset Management, LLC with notifications on news.